A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
研究单位：[1]BeiGene[2]Anhui Provincial Hospital,Hefei,Anhui,China,230000[3]The First Affiliated Hospital of Anhui Medical University,Hefei,Anhui,China,230000[4]Peking Union Medical College Hospital,Beijing,Beijing,China,100730[5]Fujian Medical University Union Hospital,Fuzhou,Fujian,China,350001[6]Fujian Cancer Hospital,Fuzhou,Fujian,China,350014[7]Lanzhou University Second Hospital,Lanzhou,Gansu,China,730030[8]The Tumor Hospital Affiliated to Guangxi Medical University,Nanning,Guangxi,China,530021[9]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China,150000[10]Anyang Cancer Hospital,Anyang,Henan,China,455001[11]Nanyang Central Hospital,Nanyang,Henan,China,473000[12]The First Affiliated Hospital of Xinxiang Medical University,Xinxiang,Henan,China,453100[13]Henan Cancer Hospital,Zhengzhou,Henan,China,450000[14]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450052[15]Hunan Cancer Hospital,Changsha,Hunan,China,410013[16]The First Peoples Hospital of Changzhou,Changzhou,Jiangsu,China,213000[17]Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School,Nanjing,Jiangsu,China,210008[18]Nantong Tumor Hospital Branch North,Nantong,Jiangsu,China,226000[19]The Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu,China,221000[20]General Hospital of Ningxia Medical University,Yinchuan,Ningxia,China,750004[21]Shandong Cancer Hospital,Jinan,Shandong,China,250117[22]The Second Affiliated Hospital of Shandong First Medical University,Taian,Shandong,China,271099[23]Sichuan Cancer Hospital and Institute,Chengdu,Sichuan,China,610041[24]Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital,Chengdu,Sichuan,China,610071[25]Tianjin Medical University Cancer Institute and Hospital,Tianjin,Tianjin,China,300060[26]National Cancer Center,Goyangsi,Gyeonggido,Korea, Republic of,10408[27]Gachon University Gil Medical Center,Incheon,Incheon Gwang'yeogsi,Korea, Republic of,21565[28]Chonnam National University Hwasun Hospital,Hwasungun,Jeonranamdo,Korea, Republic of,58128[29]Seoul National University Hospital,Seoul,Seoul Teugbyeolsi,Korea, Republic of,03080[30]Asan Medical Center,Seoul,Seoul Teugbyeolsi,Korea, Republic of,05505[31]The Catholic University of Korea, Seoul St Marys Hospital,Seoul,Seoul Teugbyeolsi,Korea, Republic of,06591[32]Korea University Guro Hospital,Seoul,Seoul Teugbyeolsi,Korea, Republic of,08308[33]Changhua Christian Hospital,Changhua,Taiwan,50006[34]Kaohsiung Medical University Chung Ho Memorial Hospital,Kaohsiung,Taiwan,807[35]National Taiwan University Hospital,Taipei,Taiwan,10048[36]Taipei Veterans General Hospital,Taipei,Taiwan,11217[37]Ramathibodi Hospital Mahidol University,Bangkok,Thailand,10400[38]Siriraj Hospital,Bangkok,Thailand,10700[39]Songklanagarind Hospital (Prince of Songkhla University),Hat Yai,Thailand,90110[40]Hrh Princess Maha Chakri Sirindhorn Medical Center (Srinakharinwirot University),Ongkharak,Thailand,26120[41]Phramongkutklao Hospital,Ratchathewi,Thailand,10400
研究目的：
This is a randomized, open-label study to compare how well LBL-007 works in combination with tislelizumab and chemotherapy versus tislelizumab and chemotherapy when given as the first-line treatment in participants with inoperable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).
